Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amsterdam Molecular Therapeutics and the US National Institutes of Health (NIH) have widened their existing licensing deal to use adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Subscribe to our email newsletter
Additionally, the US Patent and Trademark Office (USPTO) has issued a notice of allowance (NoA) to AMT for its patent application entitled ‘AAV vectors produced in insect cells,’ which covers a core asset of the company’s proprietary manufacturing technology.
The patent includes a novel and improved method of delivery of therapeutic genes to targets using adeno-associated viral (AAV) derived vectors produced in insect cells.
AMT CEO Jorn Aldag said the expansion of the company’s existing AAV5 license with NIH is an important addition to its intellectual property position as it supports its pipeline products that follow Glybera.